servations re arding genital herpes simplex virus (HSV) infections which have been published since 1989 are reviewed.
• The seroprcvalence of HSV-2 antibodies reported in adults living in the United Stales wa 16.4%. Thi figure is remarkably imjlar to the croprevalen e reported from Toronto. Ontario ala similar lime (2) . In bolh studies. eropreva lence rates were approximately 40% higher in women than in men (1.2). In the American study. infection rates were three Urnes higher in blacks than whiles (1). The seroprevalence approaches 50% in sexually transmilled clisea s clinic allenclee (3).
• Most HSV-2 seropositive individuals a re unaware of a clia<fno is of enilal herpes (3 -5). However. a mong wom en. up to 50% \viii develop recognizable genital le ions \viU1in a period of five monU1s (5).
• Asymptomatic shedding of HSV ha been slud ie repeatedly in pregnant women . ll is now clear lhal such shedding occurs in both men and nonpregnant women (6) . Stud ies from U1c National Institutes of Health in the United Stale have found lhal symptomatic shedding occurs at a rate of eight days per 1000. and this rate does not differ subs tantia lly between men and women. However. lhc rate of asymplomalic s hedd ing may have underestimated beca use culture swabs were refri<feraled for up to three days prior to inoculation of ce ll culture in that study.
• AIU1ough daily acylovir therapy markedly reduces lhe number of recurrences of genita l herpes (by about 75%) acylovir does not reduce asymptomatic hedding of HSV (6).
• Sexual transmission occurs more common ly from an asymptomatic ource patient than from a ymptomalic pati nt (7).
• As \vith other sexually tran milled diseases. HSV-2 i transmitted more effe lively from male lo female than femal to male (7).
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• The prior pre ence of HSV -1 an Ubodies in serum clearly reduces the chances of sexual transmission of HSV-2 (7). however. HSV-1 antibody doe not appear to prevent neonatal tran mission of HSV-2
• Approximately l 0% of pregnant women are boU1 HSV-2 eronegative and have HSV -2 seropo ilive sexual partners (8) . These women are clearly at risk of primary HSV-2 infection during pregnancy which is associated \vith a 40 to 50 % rate of neonatal herpe infection.
• Approximately one-U1ird of women who are a ymplomatic shedders of HSV at pai-turition have piimary HSV infections and U1U are at high risk or neonatal transmission (4).
• After primary <fen ital HSV-2 infection. asymptomatic hedding of virus is common for a period or three months (9).
• lncreasing data s upporting U1e safety of acyclovir during pregnancy have now been accrued (l 0).
These observations add substantially to our understanding of genital herpes and its sexual and neonatal transmission. The high prevalence of HSV-2 infections comb ined vviU1 U1e recognition of a ymplomatic vi ral shedding as the major route of sexual lransm i ion is yel another reason U1at safer sex practices must be promoted. Unfortunately, these studies do not ignificanUy change U1e approach lot he dia<fnosi and mana<fcmenl of such infections. Guidelines for prevention of perinatal transmission wer revised in 1987. recommending U1e abandonment of weekly gen ital cultures in patients \viU1 a positive history of genital herpes since: U1is do not id entify lhe majority of patient \vilh genital HSV inJection: U1is has not been shown to predict viral shedd ing at labour and the risk of perinalalt.ransmission in recurrent genital h e rpes i extremely low (11). Similar gu idelines have b en in endorsed in Canada (12) . Unfortunately. there is sti ll no reliable strategy to prevent most cases of neonatal herpes infection . Howeve r. many need less cesarean deliveries can be avoided and effective therapy is available for th e approximalely one in 2000 infants who develop neonatal herpes Submit your manuscripts at http://www.hindawi.com
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